The role of cGMP hydrolysing phosphodiesterases 1 and 5 in cerebral artery dilatation

By Kruuse C.   Rybalkin S.D.   Khurana T.S.   Jansen-Olesen I.   Olesen J.   Edvinsson L.  

European Journal of Pharmacology, Vol. 420, Iss. 1, 2001-05 ,pp. : 55-65

Elsevier

Access to resources Recommend Favorite

THE ACTIVATION OF SEROTONIN RECEPTORS PREVENTS GLUTAMATE-INDUCED NEUROTOXICITY AND NMDA-STIMULATED cGMP ACCUMULATION IN PRIMARY CORTICAL CELL CULTURES

By Gandolfi O.   Gaggi R.   Voltattorni M.   Dall’olio R.  

Pharmacological Research, Vol. 46, Iss. 5, 2002-11 ,pp. : 409-414

Academic Press

Access to resources Recommend Favorite

LY-83583 stimulates glucose transporter-1-mediated glucose transport independent of changes in cGMP levels

By Prasad R.K.   Behrooz A.   Ismail-Beigi F.  

European Journal of Pharmacology, Vol. 366, Iss. 1, 1999-01 ,pp. : 101-109

Elsevier

Access to resources Recommend Favorite

Inhibitors of PDE1 and PDE5 cGMP phosphodiesterases: patents and therapeutic potential

By Sybertz E.   Czarniecki M.  

Expert Opinion on Therapeutic Patents, Vol. 7, Iss. 6, 1997-06 ,pp. : 631-639

Informa Healthcare

Access to resources Recommend Favorite

Influence of phosphodiesterases and cGMP on cAMP generation and on phosphorylation of phospholamban and troponin I by 5-HT₄ receptor activation in porcine left atrium

By Weninger Sabine   Maeyer Joris   Lefebvre Romain  

Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 386, Iss. 8, 2013-08 ,pp. : 671-684

Springer Publishing Company

Access to resources Recommend Favorite